Search results
Results from the WOW.Com Content Network
CHAMPVA also has a catastrophic spending cap of $3,000 per calendar year, which is the maximum amount of out-of-pocket costs for CHAMPVA-covered supplies and services.
The American Society of Health-System Pharmacists (ASHP) reported that 323 "active medication shortages" were reported in January–March 2024. As a result of drug scarcity, many healthcare systems were forced to either ration out essential drugs, triage patients based on the severity of their condition and their need for the drug, or both.
In the US, where a system of quasi-private healthcare is in place, a formulary is a list of prescription drugs available to enrollees, and a tiered formulary provides financial incentives for patients to select lower-cost drugs. For example, under a 3-tier formulary, the first tier typically includes generic drugs with the lowest cost sharing ...
Drugs subject to USP standards include both human drugs (prescription, over-the-counter, or otherwise) and animal drugs. USP-NF standards also have a role in US federal law ; a drug or drug ingredient with a name recognized in USP-NF is considered adulterated if it does not satisfy compendial standards for strength, quality, or purity.
Martindale aims to cover drugs and related substances reported to be of clinical interest anywhere in the world. It provides health professionals with a useful source of information to identify medicines, such as confirming the drug and brand name of a medication being taken by a patient arriving from abroad.
The Medicare Prescription Drug, Improvement, and Modernization Act, [1] also called the Medicare Modernization Act or MMA, is a federal law of the United States, enacted in 2003. [2] It produced the largest overhaul of Medicare in the public health program's 38-year history.
Marstacimab was authorized for medical use in the European Union in November 2024. [3] The US Food and Drug Administration approved marstacimab in October 2024, for people aged twelve years of age and older with hemophilia A and B without inhibitors (to prevent or reduce bleeding episodes). [4] [7] [8]
Description - includes the proprietary name (if any), nonproprietary name, dosage form(s), qualitative and/or quantitative ingredient information, the pharmacologic or therapeutic class of the drug, chemical name and structural formula of the drug, and if appropriate, other important chemical or physical information, such as physical constants ...